PR Newswire updates

09.16
2026
OCI publishes Position Statement in connection with the offer of NNS for all issued and outstanding OCI shares and convenes Extraordinary General Meeting of shareholders
09.16
2026
Introducing Fotor Agent: Create Fully Editable AE-Quality Motion Graphics and Long-Form Videos
09.16
2026
ugee Unveils ArtPlay Pad: EMR-Powered Creative Tablet Turns Children's 2D Sketches Into Physical 3D Works

Qatari Diar and FTG Development Groundbreaking on Land of Legends in Simaisma
November 21, 2024
G-P Recognized as a Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 21, 2024
Emeren to Participate in Upcoming Investor Conferences
November 21, 2024
Mega Matrix Inc. Signs MOU with 9Yards Cinema Production to Establish A $100m Investment Fund for Global Short Drama and Pan-Entertainment Sector
November 21, 2024
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
November 21, 2024
3Shape A/S and Medit Corp. Reach Settlement in Patent Infringement Lawsuit
November 21, 2024
Baozun Announces Third Quarter 2024 Unaudited Financial Results
November 21, 2024
Yiren Digital Reports Third Quarter 2024 Financial Results
November 21, 2024

OCI publishes Position Statement in connection with the offer of NNS for all issued and outstanding OCI shares and convenes Extraordinary General Meeting of shareholders

This press release is issued pursuant to the provisions of Section 18…

Introducing Fotor Agent: Create Fully Editable AE-Quality Motion Graphics and Long-Form Videos

Fotor Agent, ranked No. 1 Product of the Day on Product Hunt,…

ugee Unveils ArtPlay Pad: EMR-Powered Creative Tablet Turns Children's 2D Sketches Into Physical 3D Works

ugee Unveils ArtPlay Pad: EMR-Powered Creative Tablet Turns Children's 2D Sketches Into Physical 3D Works

Designed for the way today’s youth create—anytime, anywhere, across any medium…

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

The fifteen-month dataset represents the final analysis from the Phase 1/2 study…